RE: Transcript of Brad's Latest InterviewI would rate this a confidence reducing interview. BT is a large work in progress on the mngt side of the business.
Stating basic issues as "getting a little strange", "a little bewildering", and admitting no appropriate control over trial progression ("I keep annoying my investigator" good grief), etc. is not the level of expertise a shareholder should expect of a CEO (particularly when the science is so promising). When admitting to serious managerial deficiencies is it a wonder the BPlan doesn't progress smoothly.
Biggest positives ONC could do for everyone (including themselves):
a) hire a President fully experienced in non-Canadian (ie US) cancer trials, dealing with FDA, NCI, etc. and partnering with big pharma
b) get a BoD who aren't primarily gentlemen cattle farmers from Alberta
c) BT restrict himself to CEO and Chief Science Officer (his real area of expertise and the key value creation aspect of ONC), and let the new President run the business of ONC.
Those wishing for a quick to market process may be best served by praying for a buyout from a pharma with the resources, expertise and capabilities to progress the science to commercialization.
Being bewildered and confused are not good attributes for a CEO. How long has he been CEO and still hasn't got this resolved.
Just the take of a hopeful but frustrated and disappointed long.
PS Aspen 16 what news??